The ALDH1A1 Knockout A-549 Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal knockout cell population targeting the human ALDH1A1 gene in the A-549 lung epithelial carcinoma cell line. This heterogeneous pool of edited cells carries gene disruptions introduced by CRISPR/Cas9-mediated targeting, offering a versatile loss-of-function model for studying ALDH1A1 biology without clonal isolation. The polyclonal format preserves population-level diversity, making it suitable for pooled functional screens, bulk biochemical assays, and experiments where averaging across multiple knockout alleles is advantageous.
The parental A-549 cell line is an adherent epithelial line originally derived from human lung carcinoma tissue, widely employed as a model for lung adenocarcinoma. A-549 cells recapitulate key features of lung epithelial carcinoma, including epithelial barrier function and oncogenic signaling, and are extensively used in cancer biology, drug discovery, and epithelial cell research. Their robust growth and well-characterized transcriptome facilitate reproducible gene-editing experiments and downstream functional analyses.
ALDH1A1 encodes an aldehyde dehydrogenase that catalyzes the oxidation of retinaldehyde to retinoic acid, a critical morphogen, using NAD+ as a cofactor. This reaction competes with alcohol dehydrogenase for retinaldehyde metabolism. Retinoic acid subsequently activates nuclear receptor heterodimers RAR??/RXR??, which regulate gene expression programs governing stem cell maintenance, differentiation, and apoptosis. ALDH1A1 is transcriptionally regulated by pluripotency factors SOX2, OCT4, and Nanog, and its activity influences downstream targets including HOX genes, CYP26A1, p21, and Bcl-2. Within the retinoic acid signaling cascade, RDH10 produces retinaldehyde, which ALDH1A1 converts to retinoic acid; cellular retinoic acid levels are further modulated by binding proteins such as CRABP2 and metabolic enzymes like CYP26A1. Thus, ALDH1A1 sits at a nexus controlling stem cell fate, aldehyde detoxification, and tumorigenic signaling.
In A-549 lung adenocarcinoma cells, ALDH1A1 activity is associated with cancer stem cell properties and chemoresistance. Retinoic acid signaling often drives differentiation and reduces stemness, so ALDH1A1 knockout disrupts this axis, potentially impairing the self-renewal and drug-resistant phenotype of tumor-initiating cells. The polyclonal knockout population in this lung cancer background enables investigation of ALDH1A1-dependent signaling in epithelial tumor biology without the confounding effects of clonal selection, providing a physiologically relevant model for exploring tumor heterogeneity and therapeutic vulnerabilities.
These cells are suitable for a broad range of applications: Western blotting and RT-qPCR confirm ALDH1A1 disruption; ALDEFLUOR flow cytometry assesses aldehyde dehydrogenase activity; LC-MS quantifies retinoic acid; and RARE reporter assays monitor retinoic acid response. Functional studies include sphere formation to evaluate cancer stem cell self-renewal, cell viability and drug sensitivity assays for chemoresistance, and immunofluorescence for stem cell markers. Researchers can apply this model to dissect retinoid signaling, study differentiation therapy, and investigate ALDH1A1??s role in lung adenocarcinoma. For further information, please contact Ascent Research.
